Barath Shankar Subramanian Senior Industry Analyst Frost & Sullivan North American Healthcare Practice   Daniel Ruppar Industry Manager, Pharmaceuticals & Biotechnology Frost & Sullivan John Watson Corporate Vice President President – Strategic Partnering & Integrated Drug Development Covance Josh Smiley CFO, Lilly Research Laboratories Eli Lilly & Co. The biopharmaceutical industry is experiencing a paradigm shift as new models for drug development emerge alongside an evolving CRO industry.  An approaching patent cliff and financial/regulatory pressures at all-time highs has fueled the biggest trend in drug development outsourcing -- strategic partnering.  The move from highly transactional relationships to trust-based, innovative partnerships is creating value for the biopharmaceutical industry by improving R&D productivity.    Join us for this complimentary 60 minute eBroadcast as executives from Covance and Eli Lilly discuss how strategic partnering can improve R&D productivity.  Participants will learn: The evolution of contemporary CROs Innovative solutions for more efficient R&D How an asset transfer worked for Eli Lilly Partnerships fuel the future of outsourcing Click here to register and join us as we discuss how strategic partnering can reduce your fixed R&D costs. Share and exchange your experience and viewpoints with our panel of experts during our live, interactive Q&A following the presentation.   As our appreciation to you for joining us on this eBroadcast, all participants will be entered into a giveaway for an Ipod Touch. All registrants will be eligible to receive a $500 credit voucher* toward any one of our upcoming Executive MindXchange events. * $500 Credit Voucher must be redeemed and allocated no later than Friday, January 15, 2010.